The DOI matches its Crossref record; 323 of the 323 references it cites were found in a registry or an index.
Recent advances in the multitarget‐directed ligands approach for the treatment of Alzheimer's disease
Abstract
With 27 million cases worldwide documented in 2006, Alzheimer's disease (AD) constitutes an overwhelming health, social, economic, and political problem to nations. Unless a new medicine capable to delay disease progression is found, the number of cases will reach 107 million in 2050. So far, the therapeutic paradigm one‐compound‐one‐target has failed. This could be due to the multiple pathogenic mechanisms involved in AD including amyloid β (Aβ) aggregation to form plaques, τ hyperphosphorylation to disrupt microtubule to form neurofibrillary tangles, calcium imbalance, enhanced oxidative stress, impaired mitochondrial function, apoptotic neuronal death, and deterioration of synaptic transmission, particularly at cholinergic neurons. Approximately 100 compounds are presently been investigated directed to single targets, namely inhibitors of β and γ secretase, vaccines or antibodies that clear Aβ, metal chelators to inhibit Aβ aggregation, blockers of glycogen synthase kinase 3β, enhancers of mitochondrial function, antioxidants, modulators of calcium‐permeable channels such as voltage‐dependent calcium channels,N‐methyl‐D‐aspartate receptors for glutamate, or enhancers of cholinergic neurotransmission such as inhibitors of acetylcholinesterase or butyrylcholinesterase. In view of this complex pathogenic mechanisms, and the successful treatment of chronic diseases such as HIV or cancer, with multiple drugs having complementary mechanisms of action, the concern is growing that AD could better be treated with a single compound targeting two or more of the pathogenic mechanisms leading to neuronal death. This review summarizes the current therapeutic strategies based on the paradigm one‐compound‐various targets to treat AD. A treatment that delays disease onset and/or progression by 5 years could halve the number of people requiring institutionalization and/or dying from AD. © 2011 Wiley Periodicals, Inc. Med Res Rev
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Pathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052
Sussman, J. L., Harel, M., Frolow, F., Oefner, C., Goldman, A., Toker, L., & Silman, I. (1991) · Science · doi:10.1126/science.1678899 · Cited by 2,707
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198 · cited 2×
“As referred to above, the cholinergic system is the most affected in AD patients with almost 80% of cholinergic neuron loss.(74) Early observations have demonstrated a decrease in ACh concentration within the synaptic cleft.”
BackgroundResultTau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174
A Century of Alzheimer's Disease
Goedert, M., & Spillantini, M. G. (2006) · Science · doi:10.1126/science.1132814 · Cited by 2,098
Cited by
Polypharmacology: Challenges and Opportunities in Drug Discovery: Miniperspective
Anighoro, A., Bajorath, J., & Rastelli, G. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5006463 · Cited by 1,131
A perspective on multi‐target drug discovery and design for complex diseases
Ramsay, R. R., Popovic‐Nikolic, M. R., Nikolic, K., Uliassi, E., & Bolognesi, M. L. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0181-2 · Cited by 718
Current Developments of Coumarin Compounds in Medicinal Chemistry
Peng, X.-M., L.V. Damu, G., & He Zhou, C. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319210013 · Cited by 504
Nachon, F., Carletti, E., Ronco, C., Trovaslet, M., Nicolet, Y., Jean, L., & Renard, P.-Y. (2013) · Biochemical Journal · doi:10.1042/bj20130013 · Cited by 478
Guzior, N., Wi.eckowska, A., Panek, D., & Malawska, B. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666141106122628 · Cited by 323
“such as A anti-aggregating activity [34-39], neuroprotective”
Potential Impact of the Multi-Target Drug Approach in the Treatment of Some Complex Diseases
Makhoba, X. H., Viegas Jr., C., Mosa, R. A., Viegas, F. P., & Pooe, O. J. (2020) · Drug Design, Development and Therapy · doi:10.2147/dddt.s257494 · Cited by 321
A Perspective on Multi-target Drugs for Alzheimer’s Disease
Benek, O., Korabecny, J., & Soukup, O. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.04.008 · Cited by 260
Albertini, C., Salerno, A., de Sena Murteira Pinheiro, P., & Bolognesi, M. L. (2021) · Medicinal Research Reviews · doi:10.1002/med.21699 · Cited by 179
Rodríguez-Rodríguez, C., Telpoukhovskaia, M., & Orvig, C. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.03.008 · Cited by 151
Rochais, C., Lecoutey, C., Gaven, F., Giannoni, P., Hamidouche, K., Hedou, D., Dubost, E., Genest, D., Yahiaoui, S., Freret, T., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00115 · Cited by 129
Jiang, X.-Y., Chen, T.-K., Zhou, J.-T., He, S.-Y., Yang, H.-Y., Chen, Y., Qu, W., Feng, F., & Sun, H.-P. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00463 · Cited by 122
Qiang, X., Sang, Z., Yuan, W., Li, Y., Liu, Q., Bai, P., Shi, Y., Ang, W., Tan, Z., & Deng, Y. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.02.045 · Cited by 113
Prati, F., Cavalli, A., & Bolognesi, M. (2016) · Molecules · doi:10.3390/molecules21040466 · Cited by 110
He, Q., Liu, J., Lan, J.-S., Ding, J., Sun, Y., Fang, Y., Jiang, N., Yang, Z., Sun, L., Jin, Y., et al. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.09.010 · Cited by 105
Tacrines for Alzheimer's disease therapy. III. The PyridoTacrines
de los Ríos, C., & Marco-Contelles, J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.02.005 · Cited by 63
Neuroprotective activities of natural products from marine macroalgae during 1999–2015
Alghazwi, M., Kan, Y. Q., Zhang, W., Gai, W. P., Garson, M. J., & Smid, S. (2016) · Journal of Applied Phycology · doi:10.1007/s10811-016-0908-2 · Cited by 58
Iridoids and other monoterpenes in the Alzheimer’s brain: Recent development and future prospects
Habtemariam, S. (2018) · Molecules · doi:10.3390/molecules23010117 · Cited by 55
Dual Inhibitors of AChE and BACE-1 for Reducing Aβ in Alzheimer’s Disease: From In Silico to In Vivo
Stern, N., Gacs, A., Tátrai, E., Flachner, B., Hajdú, I., Dobi, K., Bágyi, I., Dormán, G., Lőrincz, Z., Cseh, S., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113098 · Cited by 35
Choi, Y., Jeong, H. J., Liu, Q. F., Oh, S. T., Koo, B.-S., Kim, Y., Chung, I.-W., Kim, Y. S., & Jeon, S. (2017) · Molecular Neurobiology · doi:10.1007/s12035-015-9636-x · Cited by 35
Turgutalp, B., Bhattarai, P., Ercetin, T., Luise, C., Reis, R., Gurdal, E. E., Isaak, A., Biriken, D., Dinter, E., Sipahi, H., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01003 · Cited by 27
Metadata
- Authors
- León, R., Garcia, A. G., & Marco‐Contelles, J.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2011-07-26
- Volume
- 33
- Issue
- 1
- Pages
- 139-189
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W1940331911
- Cited by
- 440
- References
- 323
- FWCI
- 10.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.